Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Ovarian Neoplasms | 4 | 2012 | 407 | 0.640 |
Why?
|
| Biomarkers, Tumor | 4 | 2014 | 1048 | 0.530 |
Why?
|
| Endonucleases | 2 | 2014 | 30 | 0.430 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2012 | 39 | 0.390 |
Why?
|
| Platelet Endothelial Cell Adhesion Molecule-1 | 1 | 2009 | 57 | 0.320 |
Why?
|
| Genes, p53 | 1 | 2009 | 62 | 0.320 |
Why?
|
| Receptors, Cell Surface | 1 | 2009 | 356 | 0.280 |
Why?
|
| Antigens, CD | 1 | 2009 | 442 | 0.270 |
Why?
|
| DNA-Binding Proteins | 2 | 2014 | 1316 | 0.260 |
Why?
|
| Endometrial Hyperplasia | 1 | 2005 | 15 | 0.260 |
Why?
|
| Carcinoma, Endometrioid | 1 | 2005 | 47 | 0.250 |
Why?
|
| Progestins | 1 | 2005 | 75 | 0.250 |
Why?
|
| Endometrial Neoplasms | 1 | 2005 | 151 | 0.220 |
Why?
|
| Adenocarcinoma | 1 | 2009 | 799 | 0.210 |
Why?
|
| Carboplatin | 2 | 2012 | 139 | 0.190 |
Why?
|
| Paclitaxel | 2 | 2012 | 192 | 0.180 |
Why?
|
| Immunohistochemistry | 3 | 2014 | 1642 | 0.150 |
Why?
|
| Choline-Phosphate Cytidylyltransferase | 1 | 2014 | 3 | 0.120 |
Why?
|
| Disease-Free Survival | 2 | 2014 | 621 | 0.110 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2012 | 1361 | 0.110 |
Why?
|
| Paraffin Embedding | 1 | 2012 | 21 | 0.100 |
Why?
|
| DNA, Neoplasm | 1 | 2012 | 157 | 0.100 |
Why?
|
| Neoplasm Staging | 2 | 2012 | 1178 | 0.090 |
Why?
|
| Cisplatin | 1 | 2012 | 263 | 0.090 |
Why?
|
| Thiazoles | 1 | 2011 | 110 | 0.090 |
Why?
|
| Head and Neck Neoplasms | 1 | 2014 | 425 | 0.090 |
Why?
|
| Endoglin | 1 | 2009 | 20 | 0.080 |
Why?
|
| Thrombospondin 1 | 1 | 2009 | 19 | 0.080 |
Why?
|
| Serpins | 1 | 2009 | 27 | 0.080 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2014 | 577 | 0.080 |
Why?
|
| Combined Modality Therapy | 1 | 2012 | 1127 | 0.080 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 1 | 2009 | 68 | 0.080 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 2009 | 83 | 0.080 |
Why?
|
| Pyrimidines | 1 | 2011 | 376 | 0.070 |
Why?
|
| Neovascularization, Pathologic | 1 | 2009 | 283 | 0.070 |
Why?
|
| Predictive Value of Tests | 1 | 2012 | 1805 | 0.070 |
Why?
|
| Genotype | 1 | 2012 | 1786 | 0.070 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2012 | 1216 | 0.070 |
Why?
|
| Aged, 80 and over | 3 | 2014 | 6417 | 0.070 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2009 | 503 | 0.070 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2014 | 963 | 0.070 |
Why?
|
| Aged | 4 | 2014 | 19251 | 0.060 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2012 | 1918 | 0.060 |
Why?
|
| Middle Aged | 4 | 2014 | 26999 | 0.060 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2008 | 863 | 0.050 |
Why?
|
| Female | 6 | 2014 | 59913 | 0.050 |
Why?
|
| Lung Neoplasms | 1 | 2014 | 2207 | 0.050 |
Why?
|
| Adult | 3 | 2012 | 30718 | 0.040 |
Why?
|
| Disease Progression | 1 | 2005 | 2418 | 0.040 |
Why?
|
| Humans | 6 | 2014 | 115587 | 0.030 |
Why?
|
| Young Adult | 1 | 2012 | 10470 | 0.030 |
Why?
|
| Proto-Oncogene Proteins pp60(c-src) | 1 | 2011 | 11 | 0.020 |
Why?
|
| Cell Growth Processes | 1 | 2011 | 52 | 0.020 |
Why?
|
| Dasatinib | 1 | 2011 | 46 | 0.020 |
Why?
|
| Drug Synergism | 1 | 2011 | 317 | 0.020 |
Why?
|
| Antibodies, Monoclonal | 1 | 2014 | 1265 | 0.020 |
Why?
|
| ROC Curve | 1 | 2008 | 451 | 0.020 |
Why?
|
| Prognosis | 1 | 2014 | 3339 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2008 | 795 | 0.020 |
Why?
|
| Gene Expression | 1 | 2011 | 1435 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2014 | 4944 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2011 | 2751 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2014 | 6264 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2008 | 3022 | 0.010 |
Why?
|
| Male | 1 | 2014 | 55949 | 0.000 |
Why?
|